Patents by Inventor D. Davidson

D. Davidson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6000118
    Abstract: A sealed edge joint can be formed between two metal panels such as an outer vehicle door panel and an inner door panel, by using a flowable sealant bead between the facing surfaces of the two panels, and a thin film of uncured paint-like resin between a flange on the outer panel and the exposed surface of the inner panel. The paint film is cured to a solid impervious condition by a baking operation performed on the completed door panel assembly.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: December 14, 1999
    Assignee: Chrysler Corporation
    Inventors: David M. Biernat, George Wagner, Andy Kalson, Jr., Dennis D. Davidson, Robert Shaffer
  • Patent number: 5849720
    Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 8, 1995
    Date of Patent: December 15, 1998
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5817643
    Abstract: The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucan of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5811542
    Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: September 22, 1998
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5783569
    Abstract: The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucans receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucans of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: July 21, 1998
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5741495
    Abstract: The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: April 21, 1998
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, Gary R. Ostroff, D. Davidson Easson, Jr.
  • Patent number: 5663324
    Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 2, 1997
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros James, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5633369
    Abstract: A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 27, 1997
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5622939
    Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo. Safe and efficacious preparations of neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: April 22, 1997
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5607677
    Abstract: The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.
    Type: Grant
    Filed: December 13, 1991
    Date of Patent: March 4, 1997
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, Gary R. Ostroff, D. Davidson Easson, Jr.
  • Patent number: 5589749
    Abstract: A feedback control system which uses estimated back electromotive force(EMF) from a controlled actuator to provide feedback into the control system and improve control of the actuator. Back EMF is estimated from current through the actuator and voltage across the actuator. The estimated back EMF signal is fed back into the control system where it serves as a rate term. In the preferred embodiment the back EMF signal is used in combination with an actuator position signal which is also feedback into the control system. A complementary filter conditions both the rate and position signals for improved performance. The invention is particularly suited for controlling linear actuators which do not provide conventional rate feedback signals.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: December 31, 1996
    Assignee: Honeywell Inc.
    Inventors: Dale D. Davidson, Hamid R. Sadeghpour
  • Patent number: 5532223
    Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 2, 1996
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5504079
    Abstract: Modified yeast cell wall glucans are administered to patients who are at risk for infection due to imminent surgery, chemotherapy or other treatment which affects the immune system, in order to mobilize the cellular defense mechanisms and boost the immune response of the patient before, during and after the surgery, chemotherapy or other treatment.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: April 2, 1996
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5488040
    Abstract: The present invention relates to neutral soluble .beta.-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human mono-cytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo.
    Type: Grant
    Filed: May 11, 1993
    Date of Patent: January 30, 1996
    Assignee: Alpha-Beta Technology, Inc.
    Inventors: Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 5481238
    Abstract: Compound inductors for use in switching regulators have two or more symmetrically coupled windings so the component size is reduced as well as a reduction in power losses compared with conventional inductors. The compound inductors may be used in buck and boost regulators. The compound inductor assembly has a first inductor with a first winding on a first magnetic core, a second inductor with a second magnetic core outside the first winding of the first inductor, and a second winding around the first winding of the first inductor and the second core. One end of the first winding and the corresponding end of the second winding is connected to a common connection such that voltages from an alternating current flowing in the first winding have the same polarity in the first winding and in the second winding.
    Type: Grant
    Filed: April 19, 1994
    Date of Patent: January 2, 1996
    Assignee: Argus Technologies Ltd.
    Inventors: Bruce W. Carsten, Christopher D. Davidson
  • Patent number: 5379206
    Abstract: A switch mode power converter includes a snubber diode and a snubber capacitor arranged in series with one another across the switching element of the converter. A discharge path is provided for discharging the capacitor by including a second diode, a switch and an inductor extending in series from the node between the snubber diode and the snubber capacitor to the line side of the transformer. The inductor may be coupled to a winding in series with a diode to allow clamping of the voltage across the inductor.
    Type: Grant
    Filed: December 2, 1992
    Date of Patent: January 3, 1995
    Assignee: Argus Technologies, Ltd.
    Inventor: Christopher D. Davidson
  • Patent number: PP8911
    Abstract: A new rose variety of the Hybrid Tea class characterized by having large well formed orange-red flowers on a bush with very glossy foliage and excellent disease resistance.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: September 27, 1994
    Inventor: Harvey D. Davidson
  • Patent number: PP8921
    Abstract: A new rose variety of the Hybrid Tea class characterized by having large well formed red flowers on a bush with extremely glossy foliage and excellent disease resistance.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: October 4, 1994
    Inventor: Harvey D. Davidson
  • Patent number: PP9402
    Abstract: A new rose cultivar of the Hybrid Tea class characterized by having medium sized cream, quartered, rosette shaped, flat, fragrant flowers on a bush of moderate vigor. This plant has been designated as `Hadlace`. It will be marketed in the USA under the tradename of `Olde Lace`.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: December 19, 1995
    Inventor: Harvey D. Davidson
  • Patent number: PP9404
    Abstract: A new rose cultivar of the Hybrid Tea Class Characterized by having medium sized dark red, loosely shaped, flat, intensely fragrant flowers on a vigorous upright bush. This plant has been designated as `Hardromeo`. It will be marketed in the USA under the tradename of `Olde Romeo`.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: December 19, 1995
    Inventor: Harvey D. Davidson